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Early identification of patients with chronic kidney disease
(CKD) may allow health-care systems to implement
interventions aimed at decreasing disease progression and
eventual morbidity and mortality. Primary care in the United
Kingdom is computerized suggesting a separate screening
program for CKD may not be necessary because identifying
data already populates primary care databases. Our study
utilized a data set of 163 demographic, laboratory, diagnosis,
and prescription variables from 130 226 adults in the regions
of Kent, Manchester, and Surrey. The patients were 18 years
of age and older in a 5-year study period culminating in
November 2003. Estimated glomerular filtration rate was
calculated from the four-variable Modification of Diet in
Renal Disease equation using calibrated creatinine levels.
A valid creatinine value was recorded in almost 30% of this
cohort. The age-standardized prevalence of stage 3–5 CKD
was 10.6% for females and 5.8% for males. In these patients,
the odds ratio for hypertension was 2.1, for diabetes 1.33,
and for cardiovascular disease 1.69. Only 20% of the diabetic
people with stage 3–5 CKD had a blood pressure less than or
equal to 130/80 mm Hg. The proportion of patients with
anemia significantly rose as renal function declined. We
suggest that stage 3–5 CKD is easily detected in existing
computerized records. The associated comorbidity and
management is readily available enabling intervention and
targeting of specialist resources.
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Chronic kidney disease (CKD) is a major public health
problem imposing a substantial burden on the patients
affected and on the health-care systems caring for them. CKD
is now conventionally divided into five stages (Table 1)
following the classification proposed by the National Kidney
Foundation Kidney Disease Outcome Quality Initiative in
2002.1 Data from the third National Health and Nutrition
Examination Survey (NHANES III) demonstrated that the
number of people affected in the United States of America is
high2 and subsequent reports have detailed similar, or higher,
estimates of prevalence from various countries.3–7 The
prevalence of CKD increases exponentially with age, and we
can expect numbers to rise as the population continues to age
and the prevalence of type II diabetes increases. Cohort
studies indicate that the risk of mortality in CKD far
outweighs the risk of progression to end-stage renal disease.
Cardiovascular causes account for nearly 50% of the
mortality and CKD is an independent predictor of cardio-
vascular comorbidity.3,4,8–11
Modeling based on NHANES data suggests that whole
population screening for CKD is not a cost-effective
strategy.12 This paper describes the extent to which patients
with CKD are already known to primary care in the UK but
may not have been recognized as such or optimally managed.
Screening of at risk populations has been shown to be
effective in recognizing undiagnosed CKD.13 Primary care
physicians in the UK may already be targeting at risk
populations for serum creatinine estimation such as people
with diabetes or hypertension. Laboratory reporting of
estimated glomerular filtration rate (eGFR) from serum
creatinine has been demonstrated to improve recognition of
CKD.14 Early identification of patients with CKD may allow
implementation of multiple risk factor intervention strategies
aimed at reducing morbidity, mortality, and disease progres-
sion. However, this has yet to be proven and we have yet to
identify a comprehensive, cost-effective means of identifying
patients with CKD at an early enough stage. Primary care in
the UK is now universally computerized, many practices
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receive pathology results electronically and the majority of
patient encounters are recorded electronically.
Our hypothesis was that a separate screening program for
CKD may not be necessary because the data required for early
identification of people with CKD and associated comorbid-
ities already exists electronically in primary care computer
databases. We explored this hypothesis by initiating a program
of research under the acronym NEOERICA (NEw Opportu-
nities for Early Renal Intervention by Computerised Assess-
ment). We have already demonstrated the feasibility and
validity of this approach.15,16 In the first of these publications,
we described prevalence and risk factor recording in 112 215
patients of all ages and confirmed that we can identify patients
with CKD from primary care computer records.
This study adds to our earlier study by including a larger
adult study population; calibrating creatinine before estimation
of GFR; reporting the level of control of cardiovascular risk
factors; and the comorbidity and current management of CKD.
RESULTS
Practice population demographics (Figure 1)
The total practice population was 162 113 with a mean age of
39.9722.6 years. Female to male ratio was 0.91:1. The
population was similar to that of England and Wales in terms
of age and sex profile; however, persons aged 475 years were
overrepresented (Figure 2). The number agedX18 years was
130 226, mean age 47.2718.78 years, female to male ratio
1:1. Only 0.63% (818/130 226) of patients had ethnicity
recorded. The mean body mass index in those with both
height and weight recorded was 25.875.22 kg/m2.
Demographics of study population (adults with a valid
serum creatinine between 1 December 1998 and
30 November 2003, n¼ 38 262)
The mean age was 58.1718.1 years, and female to male ratio
was 1.3:1. Height was recorded in 76.1% of the creatinine
subset and weight in 80.8%, the mean body mass index was
27.175.5 kg/m2, (Figure 1). In the most recent 24 months of
the 5-year period, 70% of the study population had an serum
creatinine (SCr) recorded.
Renal function, recording of clinically relevant data, and
prevalence of CKD stage 3–5
Table 2 shows the age standardized rates for CKD stage 3–5,
subdivided by gender. The overall prevalence of CKD stage
3–5 was 8.5% and was higher in females, 10.6 versus 5.8% in
males. The effect of creatinine standardization was to increase
the proportion of those with stage 3 CKD by a factor of 1.75
and the proportion of those with stage 4 CKD by a factor of
1.6 (data not shown). The proportion of those with stage 5
CKD remained unchanged.
Table 3 shows the patient demographics and reported
comorbidity. There was an increased female preponderance
in the three strata of eGFR below 60 ml/min/1.73 m2. In
addition, the numbers of those aged X70 years increased as
eGFR fell; 76.7% of persons with eGFR o30 ml/min/1.73 m2
were aged X70 years.
Overall, 1.6% of the study cohort had a recording of a
renal diagnosis. The proportion of patients with a recorded
diagnosis of renal disease improved as renal function
decreased. For the eGFR stratum o30 ml/min/1.73 m2,
19.2% had a recorded renal diagnosis. Moreover, 27.4%
had a record of hematuria/proteinuria testing.
Hemoglobin levels and anemia
Concurrent hemoglobin (Hb) levels were available in 32 385
(84.6%); (Table 4). Hb values were normally distributed in
the study cohort, (mean 13.871.5 g/dl). This was also
Table 1 | National Kidney Foundation KDOQI staging for CKD
Stage of
CKD Description
GFR (ml/min/
1.73 m2)
1 Kidney damage with normal or raised GFR 490
2 Kidney damage with mildly reduced GFR 60–89
3 Moderately reduced GFR 30–59
4 Severe reduction in GFR 15–29
5 Kidney failure o15
CKD, chronic kidney disease; GFR, glomerular filtration rate; KDOQI, Kidney Dialysis
Outcomes Quality Initiative.
n=162 113
Practice population
Mean age 39.9±22.6
 years F:M 0.91:1
n=31 887
Aged<18 years
n=130 226
Adults
Mean age 47.2±18.78
 years F:M 1:1
n=89 175
 No SCr recorded
n=2789 SCr
 outside study period
n=38 262 Study population
Study period 1/12/1998 to 30/11/2003
Mean age 58.1±18.1 years F:M 1.3:1
n=41 051
SCr recorded
Mean age 57.7±18.1
years F:M 1.3:1
Figure 1 | Derivation of study population.
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evident in persons with eGFR o30 ml/min/1.73 m2, (mean
13.171.8). The proportion of people with anemia rose across
the strata of eGFR (Po0.001) and this was regardless of
definition used to define anemia.
Using multivariate analysis, we demonstrated very little
correlation between Hb and eGFR, (adjusted R2¼ 0.02).
Regardless of eGFR, females were more likely to have an Hb
o11 g/dl (crude odds ratio (OR) 1.69 (95% confidence
interval (CI) 1.44–2.00)); age adjusted (o70 years or X70
years) OR 1.63 (95% CI 1.43–1.87).
Hypertension
In the study population, blood pressure (BP) records were
available in 31 740 (94.4%) of cases. 21 332 patients were
defined as hypertensive by presence of hypertension read
code and/or BP above 140/90 and/or on antihypertensive
medication. Of these, 19 702 patients had a code for
hypertension and/or BP above 140/90, and of these 9848
patients had only a hypertension read code.
Hypertension rates were similar in males and females.
The crude OR for hypertension in patients with eGFR
o60 ml/min/1.73 m2 was 3.45 (3.23–3.57); age adjusted OR
2.1 (2.0–2.2). Table 5 shows the use of antihypertensive
medication and achieved targets by eGFR strata. Antihyper-
tensive use was highest in people with an eGFRo30 ml/min/
1.73 m2 (mean of 1.76 medications per person). Overall,
angiotensin-converting enzyme inhibitors (ACEIs)/angio-
tensin 2 receptor blockers (ARBs) were used in 33.2% of
people with hypertension, ACEI/ARB inhibitor use fell with
decreasing eGFR (w2¼ 452.8, Po0.001). Achievement of BP
targets in those with a recorded BP was relatively poor with
little difference between the eGFR strata (Table 5).
Diabetes mellitus
In the adult study population a diagnosis of diabetes was
coded in 5058/130 226, representing an adult population
prevalence of 3.9%. In the study cohort, diabetes was present
in 4063/38 262 (10.6%) and prevalence increased as GFR
decreased (w2¼ 222.4, Po0.001). For diabetic females, the
crude OR for an eGFR o60 ml/min/1.73 m2 was 1.85 (95%
CI 1.68–2.03). This was lower in diabetic males; crude OR
1.41 (95% CI 1.28–1.56). Overall, the age/gender adjusted OR
to have eGFR o60 ml/min/1.73 m2 was 1.31 (95% CI
1.21–1.41).
In those with diabetes and eGFR o60 ml/min/1.73 m2,
ACEIs/ARBs were prescribed in 690/1601 (44%), aspirin and/
or other antiplatelet agents in 621/1601 (39.6%), and lipid-
lowering therapy in 942/1601 (60.1%); (Table 6). Only
around one-fifth of people with an eGFR o60 ml/min/
1.73 m2 had a BPp130/80 mm Hg and ACEI/ARB treatment
was prescribed in 44% of cases. The proportion of diabetics
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Figure 2 | Study age and sex distribution compared to England and
Wales.
Table 2 | Age-standardized rates for stage 3–5 CKD
Age bands
Males Females
Study population *Census population
Study population
*Census population
n
Proportion with
stage 3–5 CKD n
Expected stage
3–5 CKD n
Proportion with
stage 3–5 CKD n
Expected stage
3–5 CKD
18–24 8273 0.01% 3 671 800 443.8293 7716 0.18% 3 588 900 6511.74
25–34 12 424 0.17% 4 215 200 7 124.855 10 923 0.79% 4 259 800 33 538.7
35–44 13 115 0.71% 4 381 700 31 071.15 11 988 2.69% 4 464 600 119 920
45–54 10 566 3.08% 3 856 300 118 616.1 9973 2.79% 3 920 300 109 279
55–64 9518 6.89% 3 089 600 212 941.5 9254 13.09% 3 186 200 416 954
65–74 6356 17.65% 2 307 700 407 369.3 6943 27.86% 2 639 700 735 299
75–84 3884 33.16% 1 308 300 433 854.4 5754 41.68% 1 987 300 828 214
85+ 990 44.75% 312 400 139 791.1 2549 48.61% 817 300 397 267
Total 65 126 a23 143 000 b1 351 212 65 100 a24 864 100 b2 646 984
Age-standardized
rate
5.8% 10.6%
CKD, chronic kidney disease.
*Based on UK 2001 census data.
Expected stage 3–5 CKD by age band=proportion with stage 3–5 CKD *census population.
Total for expected CKD (b)=Sum of expected CKD for age bands.
Age-standardized rate=b/a *100.
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with a glycosylated Hb greater than 7.5% was similar in those
with a eGFR o60 ml/min/1.73 m2 compared to eGFR
460 ml/ml/1.73 m2 (40.9 vs 44.4%).
Lipids
The proportion of people with hypercholesterolemia was
similar in each GFR stratum, (Table 3). After adjustment for
age and gender, the OR for hypercholesterolemia in those
with eGFR o60 ml/min/1.73 m2 was 1.09 (95% CI 0.99–1.2).
Cardiovascular disease
The proportion of people in the study cohort with
cardiovascular disease (CVD) was 19.9%. CVD was more
prevalent in the eGFRo30 ml/min/1.73 m2 stratum (50.7%),
(Table 3). The crude OR for CVD in persons with
eGFR o60 ml/min/1.73 m2 was 2.92 (95% CI 2.71–3.13) in
females and 2.86 (95% CI 2.65–3.1) in males; age/gender
adjusted OR 1.69 (95% CI 1.59–1.79). Table 7 details the
prescription of ACEI/ARB, antiplatelet agents and lipid-
lowering therapy in those with CVD. Those with eGFR
o60 ml/min/1.73 m2 were more likely to be prescribed
ACEI/ARB and antiplatelet agents. As with the total
cohort, the proportion of people with CVD treated with
ACEI/ARB, lipid-lowering therapy, and antiplatelet agents
decreased in the eGFR o30 ml/min/1.73 m2 stratum (data
not shown).
Table 3 | Demographics and recording of relevant comorbidity
o30 ml/min/1.73 m2
n=525
30–44 ml/min/
1.73 m2 n=2475
45–59 ml/min/
1.73 m2 n=8731
460 ml/min/1.73 m2
n=26 531 Total n=38 262
Demographics n (%)
F:M 341:184 1731:744 5710:3021 13 987:12 544 21 769:16 493
1.85:1 2.3:1 1.89:1 1.1:1 1.3:1
Aged 470 years 403 (76.7) 2009 (81.2) 4343 (49.7) 4136 (15.6) 10 890 (28.5)
Characteristics mean7s.d.
Age (years)* 76.8714.1 78.4710.4 69.7713.5 52.3716.8 58.1718.1
BMI (kg/m2)* 27.876.1 27.775.4 27.475.4 26.875.6 27.075.5
SBP (mm Hg)* 141.3720.8 142.6720.4 138.8718.9 131.8718.9 134.3719.4
DBP (mmHg)* 76.7711.2 77.9710.8 78.8710 78.5710.3 78.5710.3
SCr (mg/dl)* 2.8771.69 1.5270.25 1.270.17 0.9670.17 1.0770.37
GFR* 22.576.4 39.374.0 53.674.2 77.7718.8 69.6721.3
Hb (g/dl)* 13.271.8 13.571.6 13.871.5 13.971.5 13.871.5
Comorbidity n (%)
Diabetes 121 (23) 398 (16.1) 1049 (12) 2495 (9.4) 4063 (10.6)
Hypertension 461 (87.8) 2143 (86.6) 6235 (71.4) 12 493 (47.1) 21 332 (55.8)
All CVD 266 (50.7) 1056 (42.7) 2369 (27.1) 3929 (14.8) 7620 (19.9)
Hypercholesterolemia 231 (44) 1034 (41.8) 3751 (43) 11 ,014 (41.5) 16 030 (41.9)
Proteinuria/
haematuria
144 (27.4) 610 (24.6) 1086 (12.4) 2690 (10.1) 4800 (12.5)
Renal diagnosis 101 (19.2) 90 (3.6) 51 (0.6) 355 (1.3) 597 (1.6)
BMI 372 (70.1) 1834 (74.1) 6559 (75.1) 19 736 (74.4) 28 501 (74.5)
Blood pressure record 503 (95.8) 2422 (97.9) 8482 (97.1) 24 719 (93.2) 31 740 (94.4)
ANOVA, analysis of variance; BMI, body mass index; CVD, cardiovascular disease; DBP, diastolic blood pressure; GFR, glomerular filtration rate; Hb, hemoglobin; SBP, systolic
blood pressure.
*Po0.001 ANOVA, excluding ‘All’.
For conversion of SCr to mmol/l, multiply by 88.4.
Table 4 | Anemia: definitions and mean Hb by strata of GFR
GFR stratum o30 ml/min/1.73 m2 30–44 ml/min/1.73 m2 45–59 ml/min/1.73 m2 460 ml/min/1.73 m2 All
zHb tested 439 (83.6) 2057 (83.1) 7308 (83.7) 22 581 (85.1) 32 385 (84.6)
zWHO anemia 127 (28.3) 379 (18.4) 948 (13.0) 3024 (13.4) 4478 (13.8)
zKDOQI anemia 94 (21.4) 294 (14.3) 590 (8.1) 1347 (6.0) 2325 (7.2)
zHbo11 g/dl 44 (10.0) 84 (4.1) 213 (2.9) 611 (2.7) 952 (2.9)
Males 12 26 53 210 301
Females 32 58 160 401 651
*Hb males 13.571.9 13.971.6 14.171.5 14.371.5 14.271.5
*Hb females 12.971.7 13.471.5 13.671.4 13.671.4 13.571.4
ANOVA, analysis of variance; GFR, glomerular filtration rate; Hb, hemoglobin; KDOQI, Kidney Dialysis Outcomes Quality Initiative; WHO, World Health Organization.
*Po0.001 ANOVA, excluding ‘All’.
zPo0.001 w2.
Values are mean7s.d. where appropriate.
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DISCUSSION
Routinely collected primary care computer records can be
used to not only detect patients with CKD stages 3–5, but also
to describe their comorbidity and current management. We
have demonstrated in a large study population, which also
included institutionalized people, that the age-standardized
adult prevalence of stage 3–5 CKD is 8.5% (10.6% for females
and 5.8% for males). This prevalence is based on the
assumption that no untested people in the primary care
population have CKD stage 3–5 and therefore inevitably
underestimates its prevalence. In addition due to the study
design this estimate is subject to Neyman bias contributing
to the underestimate of prevalence. However, the magnitude
of the effect may be less than expected because 70% of
patients had a serum creatinine within the last 24 months of
the study period. This is discussed in detail later in the
discussion. Although because of differences in methodology
comparisons with other studies need to be viewed with
caution, the gender specific rate for CKD stage 3–5 in this
study compares to results from a population study in
Iceland17 showing age-standardized rates of 11.55 and
4.71% for females and males, respectively. Other studies
have also outlined varying prevalence rates for CKD stage
3–5. A small study from Mexico (n¼ 3564) recorded a
prevalence of 8.5% for stage 3–5 CKD,6 the PREVEND study4
from the Netherlands (n¼ 8459) reported a prevalence of
5.84%, and the AusDiab study3 from Australia (n¼ 11 247)
reported the highest prevalence of stage 3–5, 11.2%. A much
larger study from Northern Ireland (n¼ 337 618), published
in abstract only, showed an overall population prevalence
of stage 3–5 CKD of 8.0%.18 The North American
comparator is the NHANES III study (n¼ 15 625), repre-
sentative of the noninstitutionalized US population, which
reported that 4.7% of the population had stage 3–5 CKD.1
The methodologies of all of these studies clearly differ to that
used in our study, but these are the only ones in the literature
providing population prevalence estimates in the countries
quoted.
The change in prevalence engendered by creatinine
standardization is significant. In our earlier, smaller study,
we predicted a whole population prevalence of stage 3–5 CKD
of 4.9% using unstandardized creatinine data.2 For the same
study period in those aged X18 years, the age-standardized
prevalence would have been 4.93% (3.16% for males, 6.86%
for females). The effect of standardization of creatinine was
to lower eGFR and this effect was greatest at lower creatinine
levels. The proportion of those with stage 5 CKD remained
unchanged, whereas the proportion of those with stage 4
Table 5 | Number of antihypertensive medications and achieved targets
o30 ml/min/1.73 m2 30–44 ml/min/1.73 m2 45–59 ml/min/1.73 m2 460 ml/min/1.73 m2 Total
Hypertension defined 461 2143 6235 12 493 21 332
Antihypertensive medications
None 117 (25.4) 598 (27.9) 2358 (37.8) 6530 (52.3) 9603 (45)
zAverage number of antihypertensives 1.84 1.76 1.66 1.54 1.6
Use of ACEi/ARB 150 (32.5) 804 (37.5) 2679 (43) 3467 (27.8) 7100 (33.2)
Achieved targets
*BPo150/90 mm Hg 245 (53.1) 1174 (54.8) 3315 (53.2) 6279 (50.3) 11 013 (51.6)
*BPo140/85 mm Hg 142 (30.8) 574 (26.8) 1419 (22.8) 2228 (17.8) 4363 (20.4)
*BPo130/80 mm Hg 63 (13.7) 234 (10.9) 571 (9.2) 765 (6.1) 1633 (7.7)
BP, blood pressure; eGFR, estimated glomerular filtration.
Values are n (%).
zAverage number of antihypertensive medications/person on treatment in eGFR strata.
*Po0.001.
Table 6 | Diabetes, treatment, and renal function
eGFR o60 ml/
min/1.73 m2
n=1568
eGFR X60 ml/
min/1.73 m2
n=2495 P-value
ACEi/ARB 690 (44.0) 880 (35.3) Po0.001
Antiplatelet agents 621 (39.6) 711 (28.5) Po0.001
Lipid-lowering
therapy
942 (60.1) 1445 (57.9) NS
HbA1c47.5% 642 (40.9) 1108 (44.4) Po0.05
Treated hypertension 1313 (83.7) 1590 (63.7) Po0.001
BPo130/80 mm Hg
in treated
hypertensives
270 (21) 281 (11.2) Po0.001
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin 2 receptor blocker;
BP, blood pressure; eGFR, estimated glomerular filtration; HbA1c, hemoglobin A1c;
NS, not significant.
Values are n (%).
Table 7 | Prescribed treatment in those with cardiovascular
disease
Prescribed
treatment
eGFR o60 ml/
min/1.73 m2
n=3691
eGFR X60 ml/
min/1.73 m2
n=3929 P-value
ACEi/ARBs 1520 (41.1) 1352 (34.4) o0.001
Antiplatelet
agents
1899 (51.4) 1590 (40.4) o0.001
Lipid-lowering
agents
1910 (50.7) 2038 (51.9) NS
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin 2 receptor blocker;
eGFR, estimated glomerular filtration; NS, not significant.
Values are n (%).
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CKD increased by a factor of 1.6, and by a factor of 1.75 in
people with stage 3 CKD.
There are clear limitations to this cross-sectional study.
Although the age and sex profile of the study population were
similar to that of England and Wales, ethnicity was unreliably
recorded, precluding use of a correction factor for Afro-
Caribbean ethnicity in eGFR calculation by the Modification
of Diet in Renal Disease (MDRD) equation. Data from the
Office of National Statistics suggest that 1.35% of the study
population would have been of Afro-Caribbean and 4.11% of
Asian ethnicity compared to 2.85 and 4.73%, respectively, in
the population of England and Wales as a whole.19 This
mitigates against a significant overestimate of lower levels of
eGFRs despite the lack of recording of ethnicity in the study
population.
Can we assume that we have captured all those with stage
3–5 CKD? This was a cross-sectional survey of live patients, in
other words a patient whose SCr had been checked but who
had subsequently died before the data collection would not
have appeared in the primary care database at the time of the
study (Neyman bias). This will have a significant effect given
the fact that large studies have demonstrated that the risk of
death in CKD is high.8,9 In addition, when interpreting the
comorbidities and management of these patients, the fact
that there is an overrepresentation of survivors may impact
on their estimates.
Also, a SCr value was recorded in 31.5% of the adult
population and in predicting the prevalence of stage 3–5
CKD, we have assumed that those who did not have a SCr
measured would not have had a GFR of o60 ml/min/
1.73 m2. Only a small proportion of patients either had a
coded diagnosis of renal disease, or had tests for hematuria,
and/or proteinuria recorded. This poor recording was
validated by the manual search of 10 979 primary care
records.16 This suggests that a relatively small proportion of
people with CKD have been identified and coded as such in
primary care. This is an important observation and is an area
which requires future study particularly in the United
Kingdom where universal eGFR reporting by laboratories
was introduced in April 2006 by the Department of Health20
and the General Practitioner Quality and Outcomes Frame-
work (QOF)21 included an incentive for setting up registries
of patients with CKD stage 3–5 (also in April 2006) which
included BP targets for patients with CKD. The impact of
these measures on the recording of renal disease will be an
important area of study, and so too will be the effect of
increased recognition of CKD on the management of both
risk factors for progression of CKD and for associated
comorbidity.
The recording of important data such as BP, diabetes,
CVD, Hb, and lipids was sufficiently complete to enable us to
describe the associated comorbidity. Prescription data was
100% complete, allowing us to also describe the current
management of these patients.
What does the data tell us? These data clearly show an
exponential increase in prevalence of stage 3–5 CKD with age
and suggest that female gender is a predictor of lower level of
eGFR. There is a high prevalence of hypertension in patients
with eGFR o30 ml/min/1.73 m2 (87.8%) and in patients
with higher, but reduced, eGFR. Our data also tell us that
very few patients achieve the level of BP control required to
prevent progression of renal disease.22 Furthermore, the
management of those with higher eGFR was significantly
worse than those with CKD stages 3–5. A major proportion
of patients with documented hypertension received no
treatment. Of those who were prescribed treatment, patients
with stage 3–5 CKD were significantly more likely to be
prescribed ACEIs/ARBs (Po0.001) and a greater proportion
achieved lower levels of recorded BP (Po0.001 for all levels)
compared with those with higher eGFR. However, those with
an eGFR o30 ml/min/1.73 m2 were less likely to receive
ACEI/ARB than those with an eGFR 30–60 ml/min/1.73 m2.
This implies that an opportunity to practice preventive
medicine is currently being lost. Similarly, despite the wealth
of literature and national guidelines supporting and advocat-
ing the importance of control of diabetes and hypertension in
patients with diabetes, the levels of diabetic control and
achieved BP in patients at all levels of eGFR is suboptimal
and dictates the need for improvement. Our data suggest that
the potential number of patients with stage 3–5 CKD and
anemia defined by Kidney Dialysis Outcomes Quality
Initiative in the UK is 399 020 subjects. Although not all of
these may be suitable for treatment, we know that treating
low Hb improves quality of life, and observational studies
suggest that lower levels of Hb are associated with increased
mortality and hospitalization.
A large proportion of those patients with stage 3 CKD are
over the age of 75 in our cohort. We acknowledge that use of
the MDRD equation in subjects older than the population
from which the equation was derived is also a further
potential source of bias and that this area merits further
study. Furthermore, there is currently little evidence in the
elderly to support the specific use of agents to delay the
progression of CKD and although modification of cardio-
vascular risk may have an impact in the elderly, again
concrete evidence for this is lacking in the setting of CKD.
The key questions to be answered are what constitutes a
normal GFR in the elderly, what level of GFR is associated
with adverse outcomes in the elderly, are the other
determinants of adverse outcomes in CKD the same for the
elderly as for younger age groups, can the risk factors for
these adverse outcomes be modified by intervention, and if so
are the targets the same in the elderly as for younger age
groups?
Recent work from our unit demonstrated that patients
with significant CKD unknown to renal services have
increased levels of mortality with a standardized mortality
of 34.5 in those under the age of 60.7 Cardiovascular
mortality was predominant. In this study, the prevalence of
all forms of CVD was greater than the general population at
all levels of eGFR but was significantly increased in those with
stage 3–5 CKD. Prescription data suggested that the manage-
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ment of these patients could be considerably improved upon.
Although patients with stage 3–5 CKD and CVD had signi-
ficantly higher prescribing rates than those with higher levels
of eGFR, still only 50% were prescribed antiplatelet agents
and lipid-lowering therapy, and even less were prescribed
ACEIs/ARBs.
Conclusion
We have shown that it is possible to use routinely collected
primary care computer data to highlight CKD stage 3–5 and
to describe the associated comorbidity and current manage-
ment of patients with CKD stage 3–5. This approach enables
considerable numbers of patients to be highlighted who
could have improved primary care management of their risk
factors for progression of CKD and of their cardiovascular
risk, with appropriate referral to secondary care where
indicated. The next phase of this project is to develop an
expert system to use this existing data to guide patients with
CKD into the appropriate disease management pathway.
MATERIALS AND METHODS
Practice computer data were extracted and processed using an
established methodology described in detail elsewhere.15,16 Briefly, in
2003 using Morbidity Information Query and Export Syntax
(MIQUEST), a Department of Health sponsored computer program,
we extracted a retrospective dataset of 163 variables from all patients
in 17 primary care practices in Kent, Greater Manchester, and West
Surrey over a 13-year period 1990–2003. Kent represents a
predominantly Caucasian rural population with a higher proportion
of people aged over 70 years compared with the UK as a whole (13.8%
vs 11.5%). Greater Manchester represents a Northern city population
and West Surrey is an affluent commuter area southwest of London.
Morbidity Information Query and Export Syntax allows the same
searches to be run on different types of primary care databases and
extracts structured or ‘coded’ data only. Free-text, or narrative, data
cannot be searched. In a separate study, the validity of using Morbidity
Information Query and Export Syntax extracted data was checked by a
manual search of the practice records in a practice of 10 975 patients.16
From the 13-year cohort, data were analysed on adults (X18
years) with a valid SCr between the 1 December 1998 and 30
November 2003, these are referred to as the study cohort. Anyone
who had a blood test in that period but died before 1 December
2003 will not have been included in the study group cohort
(Neyman bias). The data were exported into SPSS version 12.0 for
analysis. Data were cleaned by removing duplicates and by manual
translation of out of range data.
Variables analyzed included demographic details, biochemical
and haematological laboratory data, patient history and examina-
tion data, coded diagnoses, and prescription data. All data were
recorded with the date of entry.
Estimated GFR was derived from the four-variable MDRD
equation.23 To remove systematic bias in estimated GFR,24 we
calibrated the creatinine assays used in the study. Creatinine assays
used in Kent were directly calibrated to the method employed by the
central laboratory used for the MDRD Study (Beckman Rate Jaffe/
CX3 Synchron assay).25 This in turn enabled indirect calibration of
the other creatinine assays used in the study. For descriptive
purposes, and to assess better comorbidity, patients were divided
into four strata of eGFR, namely, those with eGFR o30 ml/min/
1.73 m2, eGFR 30–44 ml/min/1.73 m2, eGFR 45–59 ml/min/1.73 m2,
and those with eGFR X60 ml/min/1.73 m2.
Comorbidities were defined as follows:
(1) Hypertension: coded diagnosis of hypertension and/or recor-
ded systolic BP4140 mm Hg or diastolic BP490 mm Hg and/
or prescription of antihypertensive treatment.
(2) Diabetes: coded diagnosis of diabetes.
(3) Anemia was defined in three different ways:
K World Health Organization (WHO) definition: o13 g/dl
in adult males and postmenopausal females and o12 g/dl
in premenopausal females and prepubertal patients).
K Kidney Dialysis Outcomes Quality Initiative definition:
o11 g/dl in premenopausal females ando12 g/dl in adult
males and postmenopausal females.17
K Hb cutoff o11 g/dl.
(4) Hypercholesterolemia: coded diagnosis and/or prescription of
cholesterol-lowering treatment and/or a total cholesterol
45 mmol/l and total cholesterol/high-density lipoprotein-
cholesterol ratio of 43.0.
(5) CVD: coded diagnosis of ischemic heart disease, peripheral
vascular disease, cardiac failure, and cerebrovascular disease.
Categorical data were summarized by counts and percentages.
Normally distributed continuous variables were summarized by
mean and s.d., nonparametric data by median values. For CKD stage
3–5 prevalence, the study cohort was subdivided into 10-year age
bands. Data were age-standardized according to population rates
from the UK 2001 census. To assess comorbidity by level of renal
function, crude ORs were reported. Mantel–Haenszel common OR
estimates were used where appropriate to adjust for potential
confounders such as age and/or gender between comorbidity and
eGFR. Achievement of target BP was based on the most recent
recorded value. To assess the relationship between Hb and GFR in
the study population, univariate analysis was performed. Con-
founders were added into a stepwise multivariate model, assessing
their effect on Hb by eGFR.
To calculate the total UK expected number of patients to have
anemia as defined by Kidney Dialysis Outcomes Quality Initiative,
we multiplied the sum of the total age-standardized expected CKD
rates for males and females by the percentage of CKD individuals
fitting the KDOQI definition for anemia.
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